Loading...
Loading...
According to a research report released this morning, Bank of America has initiated Hologic
HOLX with a Buy rating and $26 PT.
Bank of America said in the report, “We initiate Hologic (
HOLX), a leading manufacturer of medical devices focused on women's health, with a Buy rating and $26 price objective. The Buy rating is based on our expectation that Hologic's 3D Dimensions system - the first mammography system approved in the US for 3D imaging or ‘tomosynthesis' – will drive meaningful upside to consensus in 2012-14. Our $26 PO equates to 16.5x our CY13 EPS estimate of $1.58, which we view as an appropriate multiple given our belief that Hologic can drive a 10%+ EPS CAGR from 2012-14.”
Hologic closed yesterday at $21.93.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in